Targeting Mast Cells in Chronic Spontaneous Urticaria - PubMed
5 days ago
- #Mast Cell
- #Chronic Spontaneous Urticaria
- #Novel Treatment
- Chronic Spontaneous Urticaria (CSU) is a mast-cell mediated disease involving IgE and non-IgE pathways.
- Current first-line treatment for CSU is second-generation H1-antihistamines as per international guidelines.
- Emerging therapies targeting mast cells include dupilumab, BTK inhibitors, anti-KIT antibodies, JAK inhibitors, MRGPRX2 inhibitors, IL-17/IL-5 inhibitors, anti-TSLP monoclonal antibodies, and mast cell silencers.
- Lifestyle changes like low-histamine diets are also being investigated for antihistamine-refractory CSU.
- Recent advancements in targeted therapies and biomarkers aim to improve treatment personalization and response.